ClinicalTrials.gg
CompletedNCT02385097Updated Jul 15, 2021Results posted

Chloroprocaine 2% vs Ropivacaine 0.75% in Ultrasound-guided Axillary Nerve Block

A Phase 3 interventional study of Chloroprocaine HCl 2% and Ropivacaine 0.75% in Axillary Nerve Block, sponsored by Sintetica SA. Completed at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-15.

Sponsored by Sintetica SA · Phase 3, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
211
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The Study evaluate the non-inferiority of Test product (Chloroprocaine 2%) versus Reference product (Ropivacaine 0.75%) in terms of proportion of subjects with a successful block for distal upper limb surgeries Successful block: anaesthesia adequate for the surgery without any supplementation in the first 45 min.

Read the detailed description

This Study evaluate the non-inferiority of Test product (Chloroprocaine 2%) versus Reference product (Ropivacaine 0.75%) in terms of proportion of subjects with a successful block for distal upper limb surgeries, without any supplementation in the first 45 min (see definitions below), calculated from the time of readiness for surgery (complete sensory block). Successful block: anaesthesia adequate for the surgery (complete sensory block), without any supplementation in the first 45 min (even if surgery lasts for > 45 min), calculated from the time of readiness for surgery (complete sensory block). Supplementation: i.v. premedication or general anaesthesia or pre- or intra-operative systemic analgesia or additional local anaesthetic infiltration

02

Conditions studied

  • Axillary Nerve Block
03

In context

Lead sponsor

Sintetica SA is the lead sponsor of 11 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sex and surgery: male and female patients scheduled for short duration (\< 60 min) distal upper limb surgery under axillary nerve block anaesthesia
  2. Age: ≥ 18 years old
  3. (BMI): 18 - 32 kg/m2 inclusive
  4. : I-III
  5. : signed written informed consent before inclusion in the study
  6. Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the investigator and to comply with the requirements of the entire study

Exclusion criteria

Exclusion Criteria:

  1. Physical findings: abnormal physical findings which could interfere with the objectives of the study. to peripheral nerve block anaesthesia. History of neuromuscular diseases to the upper extremities
  2. Axillary status: Axillary local infections, surgical scarring and pathological lymph node enlargement
  3. : IV-V
  4. Further anaesthesia: Patients anticipated to be requiring further anaesthesia (general or local anaesthesia)
  5. Chronic pain syndromes: Patients with chronic pain syndromes (taking opioids, antidepressants, anticonvulsant agents)
  6. Allergy: ascertained or presumptive to the active principle and/or formulations ingredients; ascertained or presumptive hypersensitivity to the amide and ester-type anaesthetics
  7. Diseases: significant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine or neurological diseases that may interfere with the aim of the study; ascertained psychiatric diseases, sepsis, blood coagulation disorders, insulin dependent diabetes mellitus, terminal kidney failure
  8. Medications: Medication known to interfere with the extent of regional blocks (see chloroprocaine and ropivacaine SmPCs) for 2 weeks before the start of the study. Hormonal for females will be allowed
  9. Investigative drug studies: participation in the evaluation of any product for 3 months before this study, calculated from the first day of the month following the last visit of the previous study
  10. Drug, alcohol: history of drug or alcohol abuse
  11. Pregnancy: missing or positive pregnancy test at screening, pregnant or lactating women
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
211 participants (actual)

Study arms

  • Experimental
    Chloroprocaine HCl 2% (20 mg/mL)

    Chloroprocaine 2 % Solution for injection, single administration by axillary nerve route 20 mL

    Drug: Chloroprocaine HCl 2%

  • Active comparator
    Ropivacaine 0.75% (7.5 mg/mL)

    Ropivacaine 0.75% Solution for injection, single administration by axillary nerve route 20 mL

    Drug: Ropivacaine 0.75%

Interventions

  • Single Administration (20mL) by Axillary Nerve Route

    Also known as: Ampres

  • Single Administration (20mL) by Axillary Nerve Route

    Also known as: Naropin

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Successful Block for Distal Upper Limb Surgeries

    Percentage of patients with a successful block for distal upper limb surgeries, without any supplementation in the first 45 min, calculated from the time of readiness for surgery (complete sensory block).

    Time frame: 45 min from the time of readiness of surgery

Secondary outcomes

  1. Time to Onset of Sensory Block (Corresponding to Readiness for Surgery)

    Time period from completion of the final perineural injection (time 0 h) to achievement of sensory block in the 4 nerve territories

    Time frame: Up to 1 h after last perineural injection

  2. Time to Onset of Motor Block

    Time period from completion of the final perineural injection (time 0 h) to achievement of motor block

    Time frame: Up to 1 h after last perineural injection

  3. Time to Regression of Sensory Block

    Will be deemed to have occurred when cold sensation and sensitive perception have returned (if assessable) in any nerve territory

    Time frame: Up to 12 hrs after surgery

  4. Time to Regression of Motor Block

    Will be deemed to have occurred when motor score is ≥ 3 (Modified Bromage scale) in any nerve territory (Modified Bromage scale: 0-No movement in relevant muscle group,1-Flicker of movement in relevant muscle group,2-Ability to move relevant muscle group against gravity but inability to move against resistance,3-Reduced power but ability to move muscle group against resistance,4-Full power in relevant muscle group)

    Time frame: Up to 12 hrs after surgery

  5. Partecipants Received Rescue Anaesthesia or Rescue Analgesia

    partecipants received rescue anaesthesia or rescue analgesia from completion of the final perineural injection (time 0 hour) to administration of first rescue anaesthesia or analgesia (supplementation)

    Time frame: 45 min from the time of readiness of surgery

  6. Number of Subjects Who Received Post-operative Analgesia

    Number of subjects who received the first post-operative analgesia

    Time frame: From surgery day to 24 hrs post surgery

  7. Time to Eligibility for Home Discharge

    Time from completion of the final perineural injection (time 0 h) to the time when the criteria for discharge are met, even if, according to the hospital procedures, the patient is discharged from the hospital at a later time

    Time frame: from surgery day to 24h post surgery

  8. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Number of Participants with Treatment-emergent Adverse Events (TEAEs) occurring or worsening after the first dose of IMP

    Time frame: from surgery day to day 6 +/- 1 after surgery

  9. Neurological Symptoms

    Number of patients with Neurological Symptoms (e.g. paraesthesia, motor function problems and pain at the injection site)

    Time frame: from surgery day to day 6 +/- 1 after surgery

  10. Heart Rate

    The following normal ranges Heart Rate parameters will be used: 50-90 beats/min

    Time frame: from surgery day to 24 hrs post surgery

  11. Blood Pressure

    The following normal ranges Systolic and Diastolic Blood Pressure parameters will be used: Systolic Blood Pressure: 100-139 mmHg Diastolic Blood Pressure: 50-89 mmHg

    Time frame: from surgery day to 24 hrs post surgery

  12. SpO2

    The following normal ranges SpO2 parameters will be used: Peripheral Oxygen Saturation: ≥ 95%

    Time frame: from surgery day to 24 hrs post surgery

  13. Number of Participants With Normal Electrocardiogram (ECG) Parameters

    Number of Participants with Normal Electrocardiogram (ECG) Parameters. The following normal ranges ECG parameters will be used: Heart Rate: 50-90 beats/min PR Interval: 100-220 msec QRS Duration: ≤ 120 msec QT Interval: ≤ 500 msec

    Time frame: from surgery day to 24 hrs post surgery

07

Results

Posted Jul 15, 2021

Participant flow

From April 2015 to May 2017 in Medical clinic and Hospital

Participant flow — Overall Study
MilestoneChloroprocaine HCl 2% (20 mg/mL)Ropivacaine 0.75% (7.5 mg/mL)
Started106105
Completed106105
Not completed00

Outcome measures

PrimaryPercentage of Participants With Successful Block for Distal Upper Limb Surgeries

Percentage of patients with a successful block for distal upper limb surgeries, without any supplementation in the first 45 min, calculated from the time of readiness for surgery (complete sensory block).

Time frame:
45 min from the time of readiness of surgery
Reported as:
Count of participants · Participants
Percentage of Participants With Successful Block for Distal Upper Limb Surgeries
ParticipantsChloroprocaine HCl 2% (20 mg/mL)Ropivacaine 0.75% (7.5 mg/mL)
Percentage of Participants With Successful Block for Distal Upper Limb Surgeries9697
SecondaryTime to Onset of Sensory Block (Corresponding to Readiness for Surgery)

Time period from completion of the final perineural injection (time 0 h) to achievement of sensory block in the 4 nerve territories

Time frame:
Up to 1 h after last perineural injection
Reported as:
Median · minutes
Time to Onset of Sensory Block (Corresponding to Readiness for Surgery)
minutesChloroprocaine HCl 2% (20 mg/mL)Ropivacaine 0.75% (7.5 mg/mL)
Time to Onset of Sensory Block (Corresponding to Readiness for Surgery)10 (10 to 15)15 (10 to 15)
SecondaryTime to Onset of Motor Block

Time period from completion of the final perineural injection (time 0 h) to achievement of motor block

Time frame:
Up to 1 h after last perineural injection
Reported as:
Median · minutes
Time to Onset of Motor Block
minutesChloroprocaine HCl 2% (20 mg/mL)Ropivacaine 0.75% (7.5 mg/mL)
Time to Onset of Motor Block10 (5 to 10)10 (5 to 10)
SecondaryTime to Regression of Sensory Block

Will be deemed to have occurred when cold sensation and sensitive perception have returned (if assessable) in any nerve territory

Time frame:
Up to 12 hrs after surgery
Reported as:
Median · minutes
Time to Regression of Sensory Block
minutesChloroprocaine HCl 2% (20 mg/mL)Ropivacaine 0.75% (7.5 mg/mL)
Time to Regression of Sensory Block68 (64 to 75)451 (413 to 480)
SecondaryTime to Regression of Motor Block

Will be deemed to have occurred when motor score is ≥ 3 (Modified Bromage scale) in any nerve territory (Modified Bromage scale: 0-No movement in relevant muscle group,1-Flicker of movement in relevant muscle group,2-Ability to move relevant muscle group against gravity but inability to move against resistance,3-Reduced power but ability to move muscle group against resistance,4-Full power in relevant muscle group)

Time frame:
Up to 12 hrs after surgery
Reported as:
Median · minutes
Time to Regression of Motor Block
minutesChloroprocaine HCl 2% (20 mg/mL)Ropivacaine 0.75% (7.5 mg/mL)
Time to Regression of Motor Block65 (60 to 69)415 (388 to 460)
SecondaryPartecipants Received Rescue Anaesthesia or Rescue Analgesia

partecipants received rescue anaesthesia or rescue analgesia from completion of the final perineural injection (time 0 hour) to administration of first rescue anaesthesia or analgesia (supplementation)

Time frame:
45 min from the time of readiness of surgery
Reported as:
Count of participants · Participants
Partecipants Received Rescue Anaesthesia or Rescue Analgesia
ParticipantsChloroprocaine HCl 2% (20 mg/mL)Ropivacaine 0.75% (7.5 mg/mL)
Partecipants Received Rescue Anaesthesia or Rescue Analgesia97
SecondaryNumber of Subjects Who Received Post-operative Analgesia

Number of subjects who received the first post-operative analgesia

Time frame:
From surgery day to 24 hrs post surgery
Reported as:
Count of participants · Participants
Number of Subjects Who Received Post-operative Analgesia
ParticipantsChloroprocaine HCl 2% (20 mg/mL)Ropivacaine 0.75% (7.5 mg/mL)
Number of Subjects Who Received Post-operative Analgesia4946
SecondaryTime to Eligibility for Home Discharge

Time from completion of the final perineural injection (time 0 h) to the time when the criteria for discharge are met, even if, according to the hospital procedures, the patient is discharged from the hospital at a later time

Time frame:
from surgery day to 24h post surgery
Reported as:
Median · minutes
Time to Eligibility for Home Discharge
minutesChloroprocaine HCl 2% (20 mg/mL)Ropivacaine 0.75% (7.5 mg/mL)
Time to Eligibility for Home Discharge161 (155 to 170)355.5 (260 to 450)
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

Number of Participants with Treatment-emergent Adverse Events (TEAEs) occurring or worsening after the first dose of IMP

Time frame:
from surgery day to day 6 +/- 1 after surgery
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsChloroprocaine HCl 2% (20 mg/mL)Ropivacaine 0.75% (7.5 mg/mL)
Number of Participants With Treatment-emergent Adverse Events (TEAEs)5876
SecondaryNeurological Symptoms

Number of patients with Neurological Symptoms (e.g. paraesthesia, motor function problems and pain at the injection site)

Time frame:
from surgery day to day 6 +/- 1 after surgery
Reported as:
Count of participants · Participants
Neurological Symptoms
ParticipantsChloroprocaine HCl 2% (20 mg/mL)Ropivacaine 0.75% (7.5 mg/mL)
burning : discharge81
burning : day 764
tingling : discharge825
tingling : day 756
Pins and needles sensation : discharge15
Pins and needles sensation : day 720
Pricking : discharge85
Pricking : day 700
aching : discharge106
aching : day 743
numbness : discharge227
numbness : day 723
hypoesthesia : discharge514
hypoesthesia : day 755
Pain surgery site : discharge01
Pain surgery site : day 700
diffuse hair loss : discharge00
diffuse hair loss : day 701
headache : discharge00
headache : day 720
itching : discharge00
itching : day 701
SecondaryHeart Rate

The following normal ranges Heart Rate parameters will be used: 50-90 beats/min

Time frame:
from surgery day to 24 hrs post surgery
Reported as:
Mean · beats/minutes
Heart Rate
beats/minutesChloroprocaine HCl 2% (20 mg/mL)Ropivacaine 0.75% (7.5 mg/mL)
screening73 ± 1273.6 ± 12.3
baseline72.5 ± 10.871.6 ± 12.5
discharge71.5 ± 11.573 ± 12.3
SecondaryBlood Pressure

The following normal ranges Systolic and Diastolic Blood Pressure parameters will be used: Systolic Blood Pressure: 100-139 mmHg Diastolic Blood Pressure: 50-89 mmHg

Time frame:
from surgery day to 24 hrs post surgery
Reported as:
Mean · mmHg
Blood Pressure
mmHgChloroprocaine HCl 2% (20 mg/mL)Ropivacaine 0.75% (7.5 mg/mL)
Systolic Blood Pressure at screening137 ± 20.5136.2 ± 18.2
Systolic Blood Pressure at baseline136.6 ± 18.9138 ± 19.1
Systolic Blood Pressure at discharge130.5 ± 17.8130.1 ± 17.3
Diastolic Blood Pressure at screening80.8 ± 11.480.5 ± 9.8
Diastolic Blood Pressure at baseline78.2 ± 10.780.1 ± 10.4
Diastolic Blood Pressure at discharge74.4 ± 11.175.4 ± 9.8
SecondarySpO2

The following normal ranges SpO2 parameters will be used: Peripheral Oxygen Saturation: ≥ 95%

Time frame:
from surgery day to 24 hrs post surgery
Reported as:
Mean · percentage of SpO2
SpO2
percentage of SpO2Chloroprocaine HCl 2% (20 mg/mL)Ropivacaine 0.75% (7.5 mg/mL)
baseline97.05 ± 1.5197.36 ± 1.69
discharge97.47 ± 1.5297.61 ± 1.33
SecondaryNumber of Participants With Normal Electrocardiogram (ECG) Parameters

Number of Participants with Normal Electrocardiogram (ECG) Parameters. The following normal ranges ECG parameters will be used: Heart Rate: 50-90 beats/min PR Interval: 100-220 msec QRS Duration: ≤ 120 msec QT Interval: ≤ 500 msec

Time frame:
from surgery day to 24 hrs post surgery
Reported as:
Count of participants · Participants
Number of Participants With Normal Electrocardiogram (ECG) Parameters
ParticipantsChloroprocaine HCl 2% (20 mg/mL)Ropivacaine 0.75% (7.5 mg/mL)
Number of Participants With Normal Electrocardiogram (ECG) Parameters105104

Adverse events

Collected over 7 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Chloroprocaine HCl 2% (20 mg/mL)0/106 (0%)0/106 (0%)58/106 (54.7%)
Ropivacaine 0.75% (7.5 mg/mL)0/105 (0%)0/105 (0%)76/105 (72.4%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventChloroprocaine HCl 2% (20 mg/mL)Ropivacaine 0.75% (7.5 mg/mL)
Procedural painInjury, poisoning and procedural complications48/10641/105
HypoaestesiaNervous system disorders9/10638/105
ParaestesiaNervous system disorders17/10628/105
burning sensationNervous system disorders11/1065/105
pain in extremityMusculoskeletal and connective tissue disorders11/1065/105
injection site painGeneral disorders6/1065/105
nauseaGastrointestinal disorders1/1064/105
headacheNervous system disorders3/1061/105
sensorimotor disorderNervous system disorders0/1061/105
AlopeciaSkin and subcutaneous tissue disorders0/1061/105

Baseline characteristics

211 patients were enrolled in the study. 106 of the enrolled patients were randomised to the Test treatment group and 105 patients to the Reference treatment group.

Age, Continuous
Age, Continuous(years)Chloroprocaine HCl 2% (20 mg/mL)Ropivacaine 0.75% (7.5 mg/mL)Total
Mean55.4 ± 15.452.6 ± 18.754 ± 17.1
Sex: Female, Male
Sex: Female, Male(Participants)Chloroprocaine HCl 2% (20 mg/mL)Ropivacaine 0.75% (7.5 mg/mL)Total
Female7160131
Male354580
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Chloroprocaine HCl 2% (20 mg/mL)Ropivacaine 0.75% (7.5 mg/mL)Total
American Indian or Alaska Native000
Asian134
Native Hawaiian or Other Pacific Islander000
Black or African American000
White104101205
More than one race112
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Chloroprocaine HCl 2% (20 mg/mL)Ropivacaine 0.75% (7.5 mg/mL)Total
Austria6262124
Switzerland444387
Body Mass Index
Body Mass Index(kg/m^2)Chloroprocaine HCl 2% (20 mg/mL)Ropivacaine 0.75% (7.5 mg/mL)Total
Mean25.58 ± 3.8325.61 ± 3.5525.60 ± 3.69
08

Study locations

1 site
  • Claudio Camponovo
    Gravesano, Lugano CH-6929, Switzerland
09

References and documents

Publications

  • Sulyok I, Camponovo C, Zotti O, Haslik W, Kostenberger M, Likar R, Leuratti C, Donati E, Kimberger O. A randomised, non-inferiority study of chloroprocaine 2% and ropivacaine 0.75% in ultrasound-guided axillary block. Sci Rep. 2021 May 11;11(1):10035. doi: 10.1038/s41598-021-89483-y. PubMed 33976374 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2015 to primary completion in May 2017, 25 months.

Results were first posted in Jul 2021, 4 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2015
First posted
Mar 11, 2015
StartActual
Apr 2015
Primary completionActual
May 2017
CompletionActual
May 2017
Results first posted
Jul 15, 2021
Last update
Jul 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02385097
Lead sponsor
Sintetica SA
Collaborators
Cross S.A.
Responsible party
Sponsor
First posted
Mar 11, 2015
Start date
Apr 2015
Primary completion
May 2017
Completion
May 2017
Results posted
Jul 15, 2021
Last update
Jul 15, 2021

Study contacts

Oliver Kimberger, Prof
principal investigator · Department of General Anesthesia and Intensive Care Medicine, Spitalgasse 23, 1090 Vienna, Austria
Claudio Camponovo, MD
principal investigator · Department of Anaesthesiology,Clinica Ars Medica,Via Cantonale, CH-6929 Gravesano, Switzerland
Andrea Saporito, MD
principal investigator · Department of Anaesthesiology, Ospedale Regionale di Bellinzona, CH-6500 Bellinzona, Switzerland

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chloroprocaine

Start the discussion